Dosing regimens for use with PCSK9 inhibitors
US10428157B2 · kind B2 · utility
6Cited by
40References
13Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Nov 12, 2014 |
| Grant date | Oct 1, 2019 |
| Priority date | — |
| Expiry date | Dec 26, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides methods for treating a PCSK9-mediated disease or a PCSK9-mediated condition. Specifically, the invention relates to methods comprising the administration of a proprotein convertase subtilisin/kexin type 9 (PCSK9) antibody or antigen binding protein, in the absence of a statin, to a subject in need thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.